Tag: Cancer: Kidney
Acute Kidney Injury Often Seen With Checkpoint Inhibitor Use
8 percent of patients receiving checkpoint inhibitor therapy experienced sustained acute kidney injury
Study Reveals Lower Predictive Ability for Renal Cancer Models
Prospective validation shows decrease in predictive ability compared with previous retrospective validations
Avelumab + Axitinib Approved for Treatment of Renal Cell Carcinoma
Treatment combination demonstrated longer progression-free survival versus sunitinib in randomized trial
FDA Approves Pembrolizumab Plus Axitinib for Advanced RCC
Drug combination approved for advanced renal cell carcinoma based on findings from KEYNOTE-426
Extra Weight in Adolescence Tied to Later Risk for Renal Cancer
Among Swedish men, overweight or obesity during adolescence tied to higher risk for renal cell carcinoma
Combo Regimens Effective for Tx of Metastatic Renal Cell Cancer
Two large trials show benefits for pembrolizumab-axitinib and avelumab-axitinib versus sunitinib
Kidney Stones Tied to Increased Renal Cell Carcinoma Risk
Risk increased for papillary RCC but not clear-cell RCC; risk for upper tract urothelial carcinoma increased
ASTRO: Stereotactic Ablative RT OK for RCC in Solitary Kidneys
Local control, cancer-specific survival at two years similar for patients with solitary, bilateral kidneys
Study Compares Treatment Options for T1a Renal Cancer
Percutaneous ablation compared with partial, radical nephrectomy for 4,310 patients aged ≥66 years
ASCO: Sunitinib Alone Noninferior in Metastatic Renal Cell Cancer
Sunitinib alone noninferior to nephrectomy plus sunitinib with respect to overall survival
